Related Experiment Video
Updated: Jun 29, 2025
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Net survival of men with localized prostate cancer after LDR brachytherapy
Santiago Uribe-Lewis1, Jennifer Uribe1, Claire Deering1
1The Stokes Centre for Urology, Royal Surrey Hospital NHS Foundation Trust, Guildford, United Kingdom.
Objectives:
To compare survival of patients who received LDR prostate brachytherapy relative to that of peers in the general population of England, UK.
Patients And Methods:
Net survival was estimated for 2472 cases treated between 2002 and 2016 using population-based analysis guidelines. Life tables adjusted for social deprivation in England from the Office for National Statistics were used to match patients by affluence based on their postcode.
Results:
The median (range) age at time of brachytherapy was 66 (55-84) years, 84% resided in Southeast England, 51% under an index of deprivation quintile 5 (most affluent), 55% were clinical stage T1 and the remainder T2. Death from any cause occurred in 270 patients at a median (range) of 7 (1-17) years postimplant. Five and 10-year estimates (95% CI) of overall survival were 96% (95-97) and 90% (89-92), and net survival 103% (102-104) and 109% (107-110) respectively. The net survival remained above 100% in all age-at-treatment and clinical stage groups.
Conclusion:
Net survival above 100% indicates patients survive longer than the matched general population. The study shows for the first time the net survival of patients treated with a radical therapy for localized prostate cancer in England. The impact of treatment choice on the long-term net survival advantage requires further investigation.
